Norinchukin Bank The Has $4.14 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Norinchukin Bank The raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,810 shares of the biopharmaceutical company's stock after buying an additional 475 shares during the quarter. Norinchukin Bank The's holdings in Regeneron Pharmaceuticals were worth $4,139,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the period. Avalon Trust Co bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $36,000. Crowley Wealth Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Finally, Private Wealth Management Group LLC raised its position in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on REGN shares. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research report on Tuesday, February 4th. Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a report on Friday, January 10th. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a report on Tuesday, February 4th. Finally, Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a "buy" rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $949.60.

Regeneron Pharmaceuticals Trading Up 0.4 %

Shares of Regeneron Pharmaceuticals stock traded up $2.36 during trading on Wednesday, hitting $587.85. 791,840 shares of the company were exchanged, compared to its average volume of 718,401. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market capitalization of $64.27 billion, a P/E ratio of 15.36, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The firm's fifty day moving average price is $642.12 and its 200 day moving average price is $732.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $525.99 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.86 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.60%. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.